Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Medigene AG

< Previous 1 2 Next >
News headline image
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
From Medigene AG
Via GlobeNewswire
News headline image
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
From Medigene AG
Via GlobeNewswire
News headline image
Medigene to Present at Upcoming Conferences
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
From Medigene AG
Via GlobeNewswire
News headline image
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
From Medigene AG
Via GlobeNewswire
News headline image
Medigene to Present at Upcoming Scientific Conferences
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Secures European Patent for its iM-TCR Technology
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG to report full year 2023 financial results on March 28, 2024
From Medigene AG
Via GlobeNewswire
News headline image
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
From Medigene AG
Via GlobeNewswire
News headline image
Medigene to Present at Upcoming Conferences
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
From Medigene AG
Via GlobeNewswire
News headline image
Medigene amends 2023 financial guidance
From Medigene AG
Via GlobeNewswire
News headline image
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
From Medigene AG
Via GlobeNewswire
News headline image
Medigene Reports Financial Results and Corporate Update for Q3 2023
From Medigene AG
Via GlobeNewswire
News headline image
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
From Medigene AG
Via GlobeNewswire
News headline image
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
From Medigene AG
Via GlobeNewswire
News headline image
Medigene AG to present at the Baader Investment Conference 2023
From Medigene AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.